Document Top

NSCLC patient case

A patient who contacted her GP after experiencing pain in her lower right arm (Dr Martin Reck)

Ask your Question

Please ensure your questions are written in English and only relate to this webcast. Questions relating to off-label information cannot be answered on this website. Contact your local Roche medical information department for more information.

»The patient in this case study had an overall survival of 22 months when bevacizumab was continued until disease progression. Is this length of survival evident in many patients?

The overall survival of 22 months demonstrated with continuation maintenance bevacizumab until disease progression in this case is consistent with data from the phase IV SAiL and ARIES studies. These studies showed non-squamous NSCLC patients responding to bevacizumab-based induction therapy followed by bevacizumab maintenance therapy achieved a median overall survival of 18.8 months (n=1,332) and 19.8 months (n=540), respectively (Dansin, et al. ESMO 2010; Kosty, et al. EMCC 2011). Similarly, a retrospective analysis of US medical records from patients who received bevacizumab until disease progression (n=403) resulted in a median overall survival of 20.9 months (Nadler, et al. Oncologist 2011). One final point of interest is that I currently have two patients who have received maintenance bevacizumab for more than 8 months with ongoing remission.

Back to Patient Cases Back to top

x

You are now leaving the www.avastin.net website. Links to all external sites are provided as a resource to our visitors. Hoffmann-La Roche Inc. ("Roche") accepts no responsibility for the content of these sites. Roche does not control these sites, and the opinions, claims, or comments expressed on these sites should not be attributed to Roche, except where indicated. We recommend that you consult with your physician or other healthcare provider to obtain more information about any Roche prescription medication.

OK Cancel